Literature DB >> 18553126

Modeling time variant distributions of cellular lifespans: increases in circulating reticulocyte lifespans following double phlebotomies in sheep.

Kevin J Freise1, John A Widness, Robert L Schmidt, Peter Veng-Pedersen.   

Abstract

Many pharmacodynamic (PD) models of cellular response assume a single and time invariant lifespan of all cells, despite the existence of a true underlying distribution of cellular lifespans and known changes in the lifespan distributions with time. To account for these features of cellular populations, a time variant cellular lifespan distribution PD model was formulated and theoretical aspects of modeling cellular populations presented. The model extends prior work assuming time variant "point distributions" of cellular lifespans (Freise et al. J Pharmacokinet Pharmacodyn 34:519-547, 2007) and models assuming a time invariant lifespan distribution (Krzyzanski et al. J Pharmacokinet Pharmacodyn 33:125-166, 2006). The formulated time variant lifespan distribution model was fitted to endogenous plasma erythropoietin (EPO), reticulocyte, and red blood cell (RBC) concentrations in sheep phlebotomized on two occasions, 8 days apart. The time variant circulating reticulocyte lifespan was modeled as a truncated and scaled Weibull distribution, with the location parameter of the distribution non-parametrically represented by an end constrained quadratic spline function. The formulated time variant lifespan distribution model was compared to the identical time invariant distribution, time variant "point distribution", and time invariant "point distribution" cellular lifespan models. Parameters of the time variant lifespan distribution model were well estimated with low standard errors. The mean circulating reticulocyte lifespan was estimated at 0.304 days, which rapidly increased over 3-fold following the first phlebotomy to a maximum of 1.03 days (P = 0.009). On average, the percentage of erythrocytes being released as reticulocytes maximally increased an estimated two-fold following the phlebotomies. The primary features of immature RBC physiology were captured by the model and gave results consistent with other estimates in sheep and humans. The comparison of the four lifespan models gave similar parameter estimates of the stimulation function and fits to the RBC data. However, the time invariant models fit the reticulocyte data poorly, while the time variant "point distribution" cellular lifespan model gave physiologically unrealistic estimates of the changes in the circulating reticulocyte lifespan under stress erythropoiesis. Thus the underlying physiology must be considered when selecting the most appropriate cellular lifespan model and not just the goodness-of-fit criteria. The proposed PD model and the numerical implementation allows for a flexible framework to incorporate time variant lifespan distributions when modeling populations of cells whose production or stimulation depends on endogenous growth factors and/or exogenous drugs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18553126      PMCID: PMC2753503          DOI: 10.1007/s10928-008-9089-1

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  28 in total

1.  Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers.

Authors:  L A Harker; L K Roskos; U M Marzec; R A Carter; J K Cherry; B Sundell; E N Cheung; D Terry; W Sheridan
Journal:  Blood       Date:  2000-04-15       Impact factor: 22.113

2.  Basic pharmacodynamic models for agents that alter production of natural cells.

Authors:  W Krzyzanski; R Ramakrishnan; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1999-10

3.  Pharmacodynamic models for agents that alter production of natural cells with various distributions of lifespans.

Authors:  Wojciech Krzyzanski; Sukyung Woo; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-03-25       Impact factor: 2.745

4.  Method of determination of the reticulocyte age distribution from flow cytometry count by a structured-population model.

Authors:  Paweł Wiczling; Wojciech Krzyzanski
Journal:  Cytometry A       Date:  2007-07       Impact factor: 4.355

5.  A system approach to pharmacodynamics. III: An algorithm and computer program, COLAPS, for pharmacodynamic modeling.

Authors:  P Veng-Pedersen; J W Mandema; M Danhof
Journal:  J Pharm Sci       Date:  1991-05       Impact factor: 3.534

Review 6.  Reticulocyte cellular indices: a new approach in the diagnosis of anemias and monitoring of erythropoietic function.

Authors:  C Brugnara
Journal:  Crit Rev Clin Lab Sci       Date:  2000-04       Impact factor: 6.250

7.  Blood volume determinations in sheep before and after splenectomy.

Authors:  K G Torrington; J S McNeil; Y Y Phillips; G R Ripple
Journal:  Lab Anim Sci       Date:  1989-11

8.  An assessment of recombinant human erythropoietin effect on reticulocyte production rate and lifespan distribution in healthy subjects.

Authors:  Wojciech Krzyzanski; Juan Jose Perez-Ruixo
Journal:  Pharm Res       Date:  2007-02-21       Impact factor: 4.200

9.  Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects.

Authors:  Wojciech Krzyzanski; William J Jusko; Mary C Wacholtz; Neil Minton; Wing K Cheung
Journal:  Eur J Pharm Sci       Date:  2005-11       Impact factor: 4.384

10.  Pharmacodynamic analysis of time-variant cellular disposition: reticulocyte disposition changes in phlebotomized sheep.

Authors:  Kevin J Freise; John A Widness; Robert L Schmidt; Peter Veng-Pedersen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-05-22       Impact factor: 2.745

View more
  16 in total

1.  Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human Epoetin Alfa and the Biosimilar HX575.

Authors:  Xiaoyu Yan; Philip J Lowe; Martin Fink; Alexander Berghout; Sigrid Balser; Wojciech Krzyzanski
Journal:  J Clin Pharmacol       Date:  2011-12-12       Impact factor: 3.126

2.  Modeling red blood cell survival data.

Authors:  Julia Korell; Frederiek E Vos; Carolyn V Coulter; John B Schollum; Robert J Walker; Stephen B Duffull
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-10-14       Impact factor: 2.745

3.  General relationship between transit compartments and lifespan models.

Authors:  Gilbert Koch; Johannes Schropp
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-06-23       Impact factor: 2.745

Review 4.  Pharmacodynamic models of age-structured cell populations.

Authors:  Wojciech Krzyzanski
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-09-16       Impact factor: 2.745

5.  Solution and implementation of distributed lifespan models.

Authors:  Gilbert Koch; Johannes Schropp
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-11-01       Impact factor: 2.745

6.  Modeling of delays in PKPD: classical approaches and a tutorial for delay differential equations.

Authors:  Gilbert Koch; Wojciech Krzyzanski; Juan Jose Pérez-Ruixo; Johannes Schropp
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-08-21       Impact factor: 2.745

Review 7.  Lifespan based indirect response models.

Authors:  Wojciech Krzyzanski; Juan Jose Perez Ruixo
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-01-03       Impact factor: 2.745

8.  Evaluation of performance of distributed delay model for chemotherapy-induced myelosuppression.

Authors:  Wojciech Krzyzanski; Shuhua Hu; Michael Dunlavey
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-02-12       Impact factor: 2.745

9.  Pharmacodynamic analysis of stress erythropoiesis: change in erythropoietin receptor pool size following double phlebotomies in sheep.

Authors:  Mohammad I Saleh; John A Widness; Peter Veng-Pedersen
Journal:  Biopharm Drug Dispos       Date:  2011-01-10       Impact factor: 1.627

10.  Pharmacodynamic modeling of the effect of changes in the environment on cellular lifespan and cellular response.

Authors:  Kevin J Freise; Robert L Schmidt; John A Widness; Peter Veng-Pedersen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-10-21       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.